Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

For those of you who wish to listen to this call in English, please select English in the Zoom Language Select button. In today's call, I would like to ask you to discuss the future information regarding the future of the U.S. Constitutional Reform Act of 1995. The actual results may be significantly different from the results discussed today. Regarding the potential factors that may make the actual results significantly different, the latest Form 20-F and and other SEC submission documents. In today's call, we will also discuss financial statements that do not comply with international accounting standards. Please refer to the presentation appendix for the definition and adjustment of these statements. Please also check the important information on the second page of today's presentation. Soredewa, honjitsu no presentation ni utsuritai tomoimasu. Shacho CEO no Julie Kim, Chief Financial Officer no Furuta Milano, R&D President no Andy Plump yori prezen wo sasete itadakimasu. Sono ato, shitsugiyo to no jikan wo moukete orimasu. Soredewa, hajimetai tomoimasu. Julie, please go ahead. Thank you, Chris. Thank you for joining us for today's earnings call focused on the first quarter of fiscal year 2026. We delivered a solid start to the fiscal year and our performance this quarter demonstrates steady progress against our strategic priorities, keeping us firmly on track to achieve our full year guidance. These achievements reflect our continued execution against the two horizons strategic roadmap we shared last quarter. Thank you for joining us today. Core revenue declined slightly at 0.5% at constant exchange rate, or CER, in line with our expectations, as momentum across our core inline brands and existing new launch brands largely offset anticipated headwinds in our matu...